Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Laura Angelats"'
Autor:
Irene Andreu-Saumell, Alba Rodriguez-Garcia, Vanessa Mühlgrabner, Marta Gimenez-Alejandre, Berta Marzal, Joan Castellsagué, Fara Brasó-Maristany, Hugo Calderon, Laura Angelats, Salut Colell, Mara Nuding, Marta Soria-Castellano, Paula Barbao, Aleix Prat, Alvaro Urbano-Ispizua, Johannes B. Huppa, Sonia Guedan
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-18 (2024)
Abstract Chimeric antigen receptor (CAR)-T cell therapy for solid tumors faces significant hurdles, including T-cell inhibition mediated by the PD-1/PD-L1 axis. The effects of disrupting this pathway on T-cells are being actively explored and controv
Externí odkaz:
https://doaj.org/article/7804df0598d54b5bb293efc2b4f633cf
Autor:
Benedetta Conte, Fara Brasó-Maristany, Adela Rodríguez Hernández, Tomás Pascual, Guillermo Villacampa, Francesco Schettini, Maria J. Vidal Losada, Elia Seguí, Laura Angelats, Isabel Garcia-Fructuoso, Raquel Gómez-Bravo, Natàlia Lorman-Carbó, Laia Paré, Mercedes Marín-Aguilera, Olga Martínez-Sáez, Barbara Adamo, Esther Sanfeliu, Beatrice Fratini, Claudette Falato, Núria Chic, Ana Vivancos, Patricia Villagrasa, Johan Staaf, Joel S. Parker, Charles M. Perou, Aleix Prat
Publikováno v:
EBioMedicine, Vol 102, Iss , Pp 105043- (2024)
Summary: Background: Early-stage triple-negative breast cancer (TNBC) displays clinical and biological diversity. From a biological standpoint, immune infiltration plays a crucial role in TNBC prognosis. Currently, there is a lack of genomic tools ai
Externí odkaz:
https://doaj.org/article/e280cec22ed2498189d321ebd159a946
Autor:
Nuria Chic, Eva Ciruelos, Cristina Saura, Europa-Azucena Gonzalez, Luís Álvarez-Vallina, Juan José Lasarte, Alena Gros, Lorea Villanueva, Jordi Canes, Laura Angelats, Aleix Prat, Tomás Pascual, Marta Santisteban, Manel Juan
Publikováno v:
Cancer Research. 83:OT2-10
Background Metastatic triple-negative breast cancer (mTNBC) exhibits a particularly poor clinical outcome, generally with rapid progression and worse overall survival (OS) than other BC subtypes. Among the few therapeutic options, chemotherapy-based
Autor:
Javier García-Corbacho, Alberto Indacochea, Azucena E. González Navarro, Iván Victoria, Débora Moreno, David Pesántez, Laura Angelats, Andrea Modrego-Sanchez, Esther Sanfeliu, Oleguer Castillo, Paula Blasco, Laura Mezquita, Nuria Viñolas, Miquel Nogué, Patricia Galván, Barbara Adamo, Neus Basté, Tamara Sauri, Manel Juan, Aleix Prat, Francesco Schettini
Publikováno v:
Scientia
Immune-checkpoint inhibitors (ICI) have revolutionized the therapeutic landscape of cancer. However, optimal patient selection is still an unmet need. One-hundred-forty-six patients with metastatic cancer candidates to ICI at the Hospital Clinic of B
Autor:
Fara Brasó-Maristany, Gaia Griguolo, Nuria Chic, Tomás Pascual, Laia Paré, Julia Maues, Patricia Galván, Maria Vittoria Dieci, Federica Miglietta, Tommaso Giarratano, Olga Martínez-Sáez, Mercedes Marín-Aguilera, Francesco Schettini, Benedetta Conte, Laura Angelats, Maria Vidal, Barbara Adamo, Montserrat Muñoz, Esther Sanfeliu, Blanca González, Ana Vivancos, Patricia Villagrasa, Joel S Parker, Charles M Perou, PierFranco Conte, Aleix Prat, Valentina Guarneri
Publikováno v:
JNCI: Journal of the National Cancer Institute. 115:332-336
In advanced HER2-positive (HER2+) breast cancer, the new antibody-drug conjugate trastuzumab deruxtecan is more effective compared with trastuzumab emtansine (T-DM1). However, trastuzumab deruxtecan can have considerable toxicities, and the right tre
Autor:
Javier García-Corbacho, Alberto Indacochea, Azucena E. González Navarro, Iván Victoria, Débora Moreno, David Pesántez, Laura Angelats, Andrea Modrego-Sanchez, Esther Sanfeliu, Oleguer Castillo, Paula Blasco, Laura Mezquita, Nuria Viñolas, Miquel Nogué, Patricia Galván, Barbara Adamo, Neus Basté, Tamara Sauri, Manel Juan, Aleix Prat, Francesco Schettini
Publikováno v:
Cancer Immunology, Immunotherapy. 72:1725-1726
Autor:
Esther Sanfeliu, Fara Brasó-Maristany, Maria Vittoria Dieci, Mercedes Marín-Aguilera, Blanca González-Farré, Gaia Griguolo, Tomas Pascual, Patricia Galván, Laura Angelats, Oleguer Castillo, Paula Blasco, Valeria Sirenko, Pedro Jares, Joan Antón Puig-Butillé, Laia Paré, Antonio Martínez, Antonio Llombart-Cussac, Javier Cortés, Ana Vivancos, Patricia Villagrasa, Joel S Parker, Charles M Perou, Aleix Prat, PierFranco Conte, Valentina Guarneri
Publikováno v:
Cancer Research. 83:P4-02
Background: The HER2DX assay is a genomic test in early-stage HER2-positive (HER2+) breast cancer that provides prognostic and predictive information. HER2DX is a supervised learning algorithm incorporating tumor size, nodal staging, and 4 gene expre
Autor:
Francis Esposito, David Pesantez, Laura Angelats, Alberto Indacochea, Joan Martinez-Vidal, Alba Cochs, Alexis Perez, Pol Sole i Bentz, Debora Moreno Fernandez, Iris Faull, Mary Luz Campillo, Lidia Garcia-Losada, Angélica Rodríguez, Pilar Vicente, Miguel Nogué, Iván Victoria, Aleix Prat, Tamara Sauri, Javier García-Corbacho
Publikováno v:
Journal of Clinical Oncology. 40:4152-4152
4152 Background: Despite huge efforts patients (pts) with advanced PDAC, still have a dismal long-term prognosis. The lack of available good-quality tissue samples for next generation sequencing (NGS) prevents from finding actionable alterations that
Autor:
H. Oliveres, Nuria Viñolas, Lydia Gaba, Francis Esposito, Laura Angelats, Estela Pineda, Miquel Nogue, Iván Victoria, Neus Basté Rotllán, Begoña Mellado, Maria Vidal, Olga Martinez Saez, T. Sauri, Laura Ferrer-Mileo, Pol Sole i Bentz, Alberto Indacochea, Javier Garcia-Corbacho, Debora Moreno Fernandez, Montserrat Muñoz, Francisco Pelegrín
Publikováno v:
Journal of Clinical Oncology. 39:3060-3060
3060 Background: Genetic profiling (GP) is essential not only for understanding tumor biology but also helps to identify potential genes for targeted therapies. At the same time, selected CT provide an individual genomic profile panel during the pre-